RECEIVED
CENTRAL FAX CENTER

**2**005/008

SEP 0 6 2005

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office,

Fax No. 1-571-273-8300 on September 6, 2005.

RESPONSE UNDER 37 CFR 1.116 EXPEDITED PROCEDURE – EXAMINING GROUP 1641

Docket No.: 014058-012840US

Client Ref. No.: 135 C4

TOWNSEND and TOWNSEND and CREW LLP

Lois M. Simón

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

DAVID A. JOHNSON ET AL.

Application No.: 10/043,086

Filed: January 8, 2002

For: AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS Examiner: Emily Le

Art Unit: 1648

SUBMISSION OF TERMINAL DISCLAIMER UNDER 37 CFR 1.116

EXPEDITED PROCEDURE – EXAMINING GROUP 1641

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the Interview Summary of August 31, 2005 in the above Application.

Applicants do not concur that the claims in this Application are necessarily rendered obvious by the claims in the cited patent. For example, US patent 6,113,918 discloses a series of compounds of the same general type as those claimed herein. However, the compounds in that patent are limited to those having 7-16 carbon atoms in the secondary acyl chain, whereas certain claims in this application call for those chains to have 6 carbon atoms (claim 57, for example, calls for all three of such chains to have 6 carbon atoms). Applicants submit that those skilled in the art would

Application No.: 10/043,086

Amendment under 37 CFR 1.116 Expedited Procedure

Examining Group 1641

<u>PATENT</u>

understand that in disclosing compounds having 7-16 carbon atom chains, the inventors of the '918 patent would have disclosed all of the compounds of their type that were expected to have the disclosed utility, and that compounds outside that range would not have been expected to possess such utility, or indeed, any utility.

Applicants also submit that there is no disclosure in the claims of the cited patents that compounds should have combinations of 6- and 10-carbon secondary acyl chains.

However, in order to expedite issuance of a patent in this Application, Applicants submit herewith a Terminal Disclaimer with respect to all three patents mentioned in the Interview Summary.

In view of the foregoing, Applicants submit that the claims in this Application are allowable and request early issuance of a Notice of Allowance...

If the Examiner believes a further telephone conference would expedite prosecution of this application, please telephone the undersigned.

Respectfully submitted,

Joel G. Ackerman Reg. No. 24,307

TOWNSEND and TOWNSEND and CREW LI

Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: (415) 576-0200 Fax: (415) 576-0300

JA:ja

60580002 v1